Medication overuse headache: Awareness, detection and treatment

CNS Drugs

Volumn 22, Issue 12, 2008, Pages 995-1004

  Rapoport, Alan M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW ENGLAND CENTER FOR HEADACHE   (United States)

Author keywords

Analgesics, therapeutic use; Antiepileptic drugs, therapeutic use; Antimigraines, adverse reactions; Antimigraines, therapeutic use; Botulinum toxin A, therapeutic use; Clonazepam, therapeutic use; Gabapentin, therapeutic use; Headache, drug induced

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BARBITURIC ACID DERIVATIVE; BOTULINUM TOXIN A; BUTALBITAL; BUTORPHANOL; CLONAZEPAM; CLONIDINE; CODEINE; DIHYDROERGOTAMINE MESILATE; ERGOTAMINE; ETIRACETAM; GABAPENTIN; HYDROCODONE; MORPHINE; NALBUPHINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PETHIDINE; TIZANIDINE; TOPIRAMATE; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

ABDOMINAL PAIN; ALOPECIA; ASTHENIA; BACKACHE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DIARRHEA; DIZZINESS; DOCTOR PATIENT RELATION; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG USE; DYSPEPSIA; HUMAN; INCREASED APPETITE; MASSAGE; MIGRAINE; NAUSEA; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; TRANSFORMED MIGRAINE; TREATMENT PLANNING; TREMOR; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME;

COMMUNICATION; FRUCTOSE; HEADACHE DISORDERS, SECONDARY; HUMANS; MEDICATION THERAPY MANAGEMENT; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; VALPROIC ACID;

EID: 55949116722     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/0023210-200822120-00003     Document Type: Review

References (72)

1. Bigal ME, Lipton RB. When migraine progresses: transformed or chronic migraine. Expert Rev Neurother 2006; 6: 297-306
2. Colas R, Munoz P, Temprano R, et al. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 2004; 62: 1338-42
3. International Classification of Disorders, Committee of the International Headache Society. Classification and diagnosis criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 2004; 24 Suppl. 1: 1-150
4. Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004; 62: 788-90
5. Scher AI, Stewart WF, Ricci JA, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003; 106: 81-9
6. Cupini LM, Calabresi P. Medication-overuse headache: pathophysiological insights. J Headache Pain 2005; 6: 199-202
7. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet 2004; 3: 475-83
8. Kudrow L. Paradoxical effects of frequent analgesic use. Adv Neurol 1982; 33: 335-41
9. Rapoport A. Analgesic rebound headache. Headache 1988; 28: 662-5
10. Rapoport A, Stang P, Gutterman DL, et al. Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996; 36: 14-9
11. Ayzenberg I, Obermann M, Nyhuis P, et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006; 26: 1106-14
12. Meskunas CA, Tepper SJ, Rapoport AM, et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 2006; 46: 766-72
13. Lake III AE. Medication overuse headache: biobehavioral issues and solutions. Headache 2006; 46 Suppl. 3: S88-97
14. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache 2006; 46: 1334-43
15. Sances G, Ghiotto N, Loi M, et al. A CARE pathway in medication-overuse headache: the experience of the Headache Centre in Pavia. J Headache Pain 2005; 6: 307-9
16. Lipton RB, Bigal E, Diamond M, et al., on behalf of the AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 6: 343-9
17. Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: clinical implications. Headache 2006; 46 Suppl. 4: S202-11
18. Couch JR. Rebound-withdrawal headache (medication overuse headache). Curr Treat Opt Neurol 2006; 8: 11-9
19. Limmroth V, Katsarava Z, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011-4
20. Dodick DW, Silberstein S, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 2007; 47: 1398-408
21. D'Amico D, Usai S, Grazzi L, et al. Quality of life and disability in primary chronic daily headaches. Neurol Sci 2003; 24 Suppl. 2: S97-100
22. Couch JR. Can medication overuse headache be treated by abrupt withdrawal of the overused agent? Nat Clin Pract Neurol 2006; 2: 654-5
23. Katsarava Z, Limmroth V, Finke M, et al. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology 2003; 60: 1682-3
24. Relja G, Granato A, Bratina A, et al. Outcome of medication overuse headache after abrupt in-patient withdrawal. Cephalalgia 2006; 26: 589-95
25. Rossi P, Di Lorenzo C, Faroni J, et al. Advice alone vs structured detoxification programmes for medication overuse headache: a prospective, randomized open-label trial in transformed migraine patients with low medical needs. Cephalalgia 2006; 26: 1097-105
26. Mei D, Ferraro D, Zelano G, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol 2006; 29: 269-75
27. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache. Neurology 2006; 66: 1894-8
28. Olesen J, Bousser M-G, Diener H-C, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-6
29. Pascual J, Fite B, Lopez-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache 2002; 42: 93-8
30. Boes CJ, Black DF, Dodick DW. Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol 2006; 26: 232-41
31. Calabresi P, Cupini LM. Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci 2005; 26: 62-8
32. Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006; 129: 543-50
33. Katsarava Z, Jensen R. Medication-overuse headache: where are we now? Curr Opin Neurol 2007; 20: 326-30
34. Smith TR, Stoneman J. Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management. Drugs 2004; 64: 2503-14
35. Fuh JL, Wang SJ, Lu SR, et al. Does medication overuse headache represent a behavior of dependence? Pain 2005; 119: 49-55
36. Sheftell FD, Atlas SJ. Migraine and psychiatric comorbidity: from theory and hypotheses to clinical application. Headache 2002; 42: 934-44
37. Hahn SR, Nelson MR, Lipton RB. Provider-patient migraine discussions: results of American Migraine Communication Study (AMCS). 58th Annual Meeting of the American Academy of Neurology; 2006 Apr 1-8; San Diego (CA)
38. Hahn SR, Cady RK, Nelson MR, et al. Improving healthcare professional-patient communication to promote more effective assessment of migraine impairment during and between attacks: results of the American Migraine Communication Study (AMCS) phase II. Diamond Headache Clinic's 20th Annual Practicing Physician's Approach to the Difficult Headache Patient; 2007 Feb 13-17; Rancho Mirage (CA)
39. Boyle D, Dwinnell B, Platt F. Invite, listen, and summarize: a patient-centered communication technique. Acad Med 2005;80: 29-32
40. Martin LR, Jahng KH, Golin CE, et al. Physician facilitation of patient involvement in care: correspondence between patient and observer reports. Behav Med 2003; 28: 159-64
41. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. MIGR-002 Study Group. JAMA 2004; 291: 965-73
42. Edmeads JG, Gawel MJ, Vickers J. Strategies for diagnosing and managing medication-induced headache. Can Fam Physician 1997; 43: 1249-54
43. Frediani F, Cannata AP, Magnoni A, et al. The patient with medication overuse: clinical management problems. Neurol Sci 2003; 24 Suppl. 2: S108-11
44. Sands GH. A protocol for butalbital, aspirin and caffeine (BAC) detoxification in headache patients. Headache 1990; 30: 491-6
45. Loder E, Biondi D. Oral phenobarbital loading: a safe and effective method of withdrawing patients with headache from butalbital compounds. Headache 2003; 43 (8): 904-9
46. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 2006; 26: 1192-8
47. Andrasik F. Behavioral treatment of migraine: current status and future directions. Expert Rev Neurother 2004; 4: 403-13
48. Fanciullacci M, De Cesaris F. Preventing chronicity of migraine. J Headache Pain 2005; 6: 331-3
49. Schwartz MS, Andrasik F, editors. Biofeedback, a practitioner's guide. 3rd ed. New York: Guilford Press, 2005
50. Penzien DB, Holroyd KA. Psychosocial interventions in the management of recurrent headache disorders: II. Description of treatment techniques. Behav Med 1994; 20: 64-73
51. Hammond DC, editor. Handbook of hypnotic suggestions and metaphors. New York: Norton and Company, 1990
52. Beck AT, Rush AJ, Shaw BF, et al. Cognitive techniques. In: Beck AT, Rush AJ, Shaw BF, et al., editors. Cognitive therapy of depression. New York: Guilford Press, 1979: 142-66
53. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. TOPMAT-MIG-201(TOPCHROME) Study Group. Cephalalgia 2007; 27: 814-23
54. Silberstein SD, Lipton RB, Dodick DW, et al., on behalf of the Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-80
55. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. MIGR-001 Study Group. Arch Neurol 2004; 61: 490-5
56. Goadsby PJ, Diener H-C, Bussone G, et al., on behalf of the TOPMAT-MIG-201 Investigators Group. Assessing the efficacy and safety of topiramate for the prevention of chronic migraine. 6th Meeting of the European Headache Federation; 2006 Apr 26; Valencia
57. Klapper J, on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17 (2): 103-8
58. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281-6
59. Landy SH, Baker JD. Divalproex ER prophylaxis in migraineurs with probable chronic migraine and probable medication-overuse headache: a case series. Pain Pract 2004; 4: 292-4
60. Depakote® (divalproex sodium): product information. North Chicago (IL): Abbott Laboratories, 2006 Jan
61. Diener HC, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. MIGR-003 Study Group. J Neurol 2004; 251: 943-50
62. Dodick DW, Bigal ME, Silberstein S, et al. Efficacy of topiramate treatment for chronic migraine in patients with medication overuse. Diamond Headache Clinic's 20th Annual Practicing Physician's Approach to the Difficult Headache Patient; 2007 Feb 13-17; Rancho Mirage (CA)
63. Mathew NT. Antiepileptic drugs in migraine prevention. Headache 2001; 41 Suppl. 1: S18-24
64. Bigal ME, Krymchantowski AV, Rapoport AM. Prophylactic migraine therapy: emerging treatment options. Curr Pain Headache Rep 2004; 8: 178-84
65. Kaniecki R. Neuromodulators for migraine prevention. Headache 2008; 48: 586-600
66. Calabresi P, Galletti F, Rossi C, et al. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 2007; 28: 188-95
67. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008; 22: 27-47
68. Spierings EL. Migraine mechanism and management. Otolaryngol Clin North Am 2003; 36: 1063-78
69. White HS. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 2005; 45 Suppl. 1: S48-56
70. Kuzniecky R, Ho S, Pan J, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 2002; 58: 368-72
71. Eross EJ, Gladstone JP, Lewis S, et al. Duration of migraine is a predictor for response to botulinum toxin type A. Headache 2005; 45: 308-14
72. Evers S. Status on the use of botulinum toxin for headache disorders. Curr Opin Neurol 2006; 19: 310-5